ReSound ONE: an entirely new class of hearing aids that offers a truly individualized hearing experience and the best sound quality for every user
GN Hearing, the global leader in hearing aid innovation, today unveils ReSound ONETM, a revolutionary new hearing aid* that solves one of the most enduring challenges for people with hearing loss. This unique solution places an additional microphone inside the ear canal, for the first time, allowing people relying on hearing aids to experience the world with their own ears while preserving the comfort of an open-fit device. Now every user can enjoy the benefits of superior sound quality and hear conversations better in noisy environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200818005077/en/
ReSound ONE: an entirely new class of hearing aids that offers a truly individualized hearing experience and the best sound quality for every user
With its Organic Hearing philosophy, GN has always taken its design inspiration from how humans hear naturally and seeks to mimic this within its technology as closely as possible. Following this approach, ReSound ONE uniquely adapts to the needs and lifestyle of every individual rather than the other way around.
The outer ear (pinna) is designed by nature to work like an acoustic antenna. It helps the brain localize and tune in to a particular sound, for example when listening to a specific voice in a crowded café. However, the most popular styles of hearing aids (Receiver-In-Ear and Behind-The-Ear models) capture sound from microphones that sit behind the ear and then approximate the effect of the pinna. The result is an averaged and incomplete reproduction of sound, making it hard for the brain to achieve its natural localization and noise-cancelling function. In fact, of the 79 million people who wear hearing aids globally,1 93% report having trouble hearing in noisy environments and 55% get confused about where sounds come from.2
ReSound ONE is the world’s first full-featured* hearing aid with a Microphone & Receiver-In-Ear design (M&RIE) that uses the unique shape of every individual’s ear to collect sound. This remarkable innovation has been achieved with a radical new receiver system combined with all-new Digital Feedback Suppression (DFS Ultra III), enabled by GN’s new and most powerful sound-processing chipset ever. By picking up sound directly inside the ear, ReSound ONE gives the brain everything it needs to tune in to individual voices, as well as significantly reducing background noise. Clinical studies show that all hearing aid users benefit from listening to sounds collected with their own ears, with 90% of users preferring the sound quality of ReSound ONE with M&RIE instead of only the microphone behind the ear.3,4
GN Hearing CEO and President, Gitte Aabo explains, “I am very proud that, once again, GN is first in the industry with ground-breaking innovation that will make a genuine difference in how people experience conversations and sounds around them. Placing a microphone into the ear with an open-fit hearing aid is something the industry has battled for many years to achieve. This technology will allow people with hearing loss to feel that they are literally getting their own hearing back and hearing the way nature intended. ReSound ONE will boost the communication, relationships, and confidence of every individual.”
Additionally, ReSound ONE incorporates new All Access Directionality and the user-activated Ultra Focus settings. These enhanced operating modes significantly improve speech recognition while preserving spatial perception in complex sound and noise situations. ReSound ONE includes unmatched rechargeability and extensive connectivity options to both iOS and Android™ smartphones for streaming and hearing aid control.
ReSound ONE is available from August 27, 2020 in rechargeable and non-rechargeable models. This technology is also available in new Beltone Imagine hearing aids.
Learn more about GN’s 2020 and beyond strategy with focus on individualized customer experiences.
- ENDS –
NOTES TO EDITORS
ReSound hearing aids, available from leading hearing care professionals, continue to set worldwide standards for quality and intuitive technology to help people with hearing loss communicate better than ever before. ReSound was the first hearing aid brand to be Made for iPhone, bringing direct streaming from hearing aids into the iPhone era. It also pioneered the development of 2.4 GHz wireless technology and made it possible to receive advanced at-home hearing care during COVID-19. The introduction of this new class of hearing technology with ReSound ONE demonstrates that ReSound is the undisputed innovation leader putting people with hearing loss at the center. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.
About GN Group
The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).
*ReSound ONE introduces the world’s first full-featured hearing aid with M&RIE for a truly individualized, more complete sound experience. Full-featured means a microphone in the ear and two additional, standard directional microphones, directionality features and wireless audio streaming.
© 2020 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC.
- World Health Organization (2020) Deafness and hearing loss. Factsheet. https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss. Accessed: July, 2020
- MarkeTrak 2019
- Jespersen et al (2020): M&RIE receiver preferred for sound quality and localization. ReSound white paper
- Groth J. (2020). An innovative RIE with microphone in the ear lets users “hear with their own ears”. ReSound white paper
Press and the media
Marie Schleimann Nordlund
Head of PR, Media and Communication
Tel: +45 31 26 37 34
Lars Otto Andersen-Lange
Head of External Relations & Global Public Affairs
Tel: +45 45 75 02 55
Investors and analysts
VP – Investor Relations & Treasury
Tel: +45 45 75 46 07
Senior Manager – Investor Relations
Tel: +45 45 75 92 57
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom